Details of the Drug Combinations

General Information of This Drug (ID: DM1BV7W)

Drug Name

Aliskiren DM1BV7W

Synonyms

Rasilez; SPP 100; Rasilez (TN); Tekturna (TN); Aliskiren (USAN/INN); (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-N-(2-Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]octanamide; Octanamide, .delta.-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-.gamma.-hydroxy-4-methoxy-3-(3-methoxypropoxy)-.alpha.,.zeta.-bis(1-methylethyl)-, [.alpha.S-(alpha.R*,.gamma.R*,.delta.R*,.zeta.R*)]

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

61 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acamprosate + Aliskiren	DCU7CN1	Acamprosate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Albendazole + Aliskiren	DCFRSPY	Albendazole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Aprepitant	DCE00KL	Aprepitant	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Gefitinib	DCN37U6	Gefitinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Dantrolene	DCXQNB4	Dantrolene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Kanamycin	DC8BMMQ	Kanamycin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Terazosin	DCO6MGH	Terazosin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Chlorphenesin	DCSCKNR	Chlorphenesin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Fomepizole	DC5Y9WC	Fomepizole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Triapine	DC9WBBG	Triapine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Acitretin	DC4EZ3B	Acitretin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Metyrosine	DCSR6V1	Metyrosine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Eflornithine	DCCL7EP	Eflornithine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Tiagabine	DC86TKP	Tiagabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + GINKGOLIDE A	DC6KXW6	GINKGOLIDE A	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Fenoprofen	DC5ETGX	Fenoprofen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Idarubicin	DCIGMDO	Idarubicin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Imatinib	DC8N9TO	Imatinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Linagliptin	DCWCH9P	Linagliptin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Methylene blue	DCWEF2M	Methylene blue	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Trimethobenzamide	DCCOFFO	Trimethobenzamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Maprotiline	DCRAE28	Maprotiline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Acetohexamide	DCJV3WS	Acetohexamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Brincidofovir	DCPY4C1	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Valproic Acid	DC9JTX4	Valproic Acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Naltrexone	DCG3K1I	Naltrexone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Mefloquine	DCZSCP5	Mefloquine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Doxorubicin	DCEZDD4	Doxorubicin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Auranofin	DCDLX8Q	Auranofin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Metaxalone	DCQVA6K	Metaxalone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Aciclovir	DC3T340	Aciclovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + Tacrolimus	DCM51U0	Tacrolimus	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Aliskiren + L-165041	DCKL8WY	L-165041	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
BIO-300 + Aliskiren	DC3J7T0	BIO-300	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Brincidofovir + Aliskiren	DC997I1	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
BRL-15572 + Aliskiren	DCBSY8M	BRL-15572	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Bumetanide + Aliskiren	DCC3U9E	Bumetanide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Busulfan + Aliskiren	DCISUEU	Busulfan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Cerivastatin + Aliskiren	DCP6OX0	Cerivastatin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Cilostazol + Aliskiren	DC13HNK	Cilostazol	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Clascoterone + Aliskiren	DCUFHGE	Clascoterone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Cytarabine + Aliskiren	DCFO8EB	Cytarabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Dihydroergotamine + Aliskiren	DCSAX0J	Dihydroergotamine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Epinephrine + Aliskiren	DCJC8GI	Epinephrine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Flavonoid derivative 1 + Aliskiren	DCP9SBE	Flavonoid derivative 1	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Hyodeoxycholic acid + Aliskiren	DC2D9FM	Hyodeoxycholic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
IT-141 + Aliskiren	DCFHJH1	IT-141	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
JZL195 + Aliskiren	DCH1EYU	JZL195	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Lacosamide + Aliskiren	DCONPDB	Lacosamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Leflunomide + Aliskiren	DC7IB5C	Leflunomide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maprotiline + Aliskiren	DCF8KQL	Maprotiline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Mycophenolic acid + Aliskiren	DCFICPB	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
PF-02545920 + Aliskiren	DCEQ96Y	PF-02545920	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Procarbazine + Aliskiren	DCITIN8	Procarbazine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Quinine + Aliskiren	DC9TT2Q	Quinine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Testolactone + Aliskiren	DCM9NK9	Testolactone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Tetracycline + Aliskiren	DCQJ0NN	Tetracycline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Topotecan + Aliskiren	DC3ZOB0	Topotecan	Chronic myelogenous leukemia (Cell Line: KBM-7)	[3]
Trihexyphenidyl + Aliskiren	DCXHFT8	Trihexyphenidyl	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Trimethobenzamide + Aliskiren	DCF3HVF	Trimethobenzamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Tropisetron + Aliskiren	DCG2C8C	Tropisetron	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 61 DrugCom(s)

18 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Aliskiren + Amlodipine	DCI88F3	Amlodipine	Hypertension With Metabolic Syndrome	[4]
Aliskiren + Amlodipine	DCNKDMM	Amlodipine	Hypertension	[5]
Aliskiren + Valsartan	DCS7PNS	Valsartan	Hypertension	[6]
Aliskiren + Valsartan	DC0NJ59	Valsartan	Hypertension	[6]
Aliskiren + Captopril	DC186MJ	Captopril	Type 2 Diabetes Mellitus	[7]
Aliskiren + Atenolol	DC3NG06	Atenolol	Marfan Syndrome	[8]
Aliskiren + Losartan	DC62OED	Losartan	Diabetes Mellitus	[9]
Aliskiren + Amlodipine	DC87PHA	Amlodipine	Hypertension	[10]
Aliskiren + Ramipril	DCE62MP	Ramipril	Heart Failure	[11]
Aliskiren + Enalapril	DCGGKY4	Enalapril	Chronic Heart Failure	[12]
Aliskiren + Hydrochlorothiazide	DCN1VK5	Hydrochlorothiazide	Cardiovascular Events	[13]
Aliskiren + Hydrochlorothiazide	DCRZNJ4	Hydrochlorothiazide	Hypertension	[14]
Aliskiren + Valsartan	DCMA0K9	Valsartan	Acute coronary syndrome	[15]
Aliskiren + Spironolactone	DC7F3G3	Spironolactone	Metabolic Diseases	[16]
Aliskiren + Aliskiren	DCMRGW9	Aliskiren	Metabolic Diseases	[16]
Aliskiren + Amlodipine	DC40W1W	Amlodipine	Hypertension	[17]
Aliskiren + Amlodipine	DCEQJAX	Amlodipine	Essential Hypertension	[18]
Aliskiren + Amlodipine	DCIVDAV	Amlodipine	Essential Hypertension ( Mild to Moderate)	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4812).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4	ClinicalTrials.gov (NCT00542269) Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
5	ClinicalTrials.gov (NCT00402103) An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
6	ClinicalTrials.gov (NCT00386607) A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
7	ClinicalTrials.gov (NCT00660309) A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
8	ClinicalTrials.gov (NCT01715207) Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
9	ClinicalTrials.gov (NCT00732407) Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)
10	ClinicalTrials.gov (NCT00778921) Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
11	ClinicalTrials.gov (NCT00923156) Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
12	ClinicalTrials.gov (NCT00853658) Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
13	ClinicalTrials.gov (NCT01259297) A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
14	ClinicalTrials.gov (NCT00787605) Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
15	ClinicalTrials.gov (NCT00409578) Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome. U.S. National Institutes of Health.
16	ClinicalTrials.gov (NCT01103245) Aldosterone and the Metabolic Syndrome
17	ClinicalTrials.gov (NCT00797862) Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
18	ClinicalTrials.gov (NCT00667719) A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
19	ClinicalTrials.gov (NCT00765947) Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension